Biogen files PLA for Avonex beta interferon multiple sclerosis treatment.
Executive Summary
BIOGEN AVONEX FILING IS FIRST PROPRIETARY PLA FILING for the Cambridge, Mass.-based company, Biogen noted when it reported that it filed a PLA May 22 for its recombinant interferon beta for treatment of multiple sclerosis. "This is the first time Biogen has filed in the U.S. for regulatory approval of a proprietary Biogen drug," Biogen said.